Based on the tumor size and Human epidermal growth factor receptor-2 (HER2/erbB-2) expression status, patients with ERα-positive breast cancer are initially considered for endocrine therapy to reduce the risk of malignancy and tumor recurrence after treatment [6]. This evidence concerns the gene ERBB2 and breast cancer.